aibio
Financings ·
Compass Therapeutics prices $119,999,329 stock and warrant offering at $3.00
Compass is selling 33,290,000 shares and pre-funded warrants for 6,710,000 shares. Proceeds before expenses are $112,800,000.
CMPX Compass Therapeutics, Inc.
Compass Therapeutics (CMPX) news CMPX offering news
Latest Compass Therapeutics news
We have not published a story on Compass Therapeutics yet. When there is news, it will appear here.
Compass Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $56.0 million | $42.3 million |
| Net income (loss) | -$66.5 million | -$49.4 million |
| Cash from operations | -$49.1 million | -$44.9 million |
| Cash and equivalents | $30.6 million | $43.5 million |
| Short-term investments | $178.3 million | $83.2 million |
Questions about Compass Therapeutics
Has Compass Therapeutics raised money recently?
Our latest story on this, dated Aug 12, 2025: "Compass Therapeutics prices $119,999,329 stock and warrant offering at $3.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Compass Therapeutics?
Compass Therapeutics, Inc. trades under the ticker CMPX on NASDAQ.
Where is Compass Therapeutics listed?
Compass Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Compass Therapeutics?
The SEC Central Index Key (CIK) for Compass Therapeutics, Inc. is 1738021. Its filings are on SEC EDGAR.
How many shares does Compass Therapeutics have outstanding?
180,087,915 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Compass Therapeutics listed under?
Our directory records Compass Therapeutics, Inc. under United States.
What does Compass Therapeutics do?
Our directory classifies Compass Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Compass Therapeutics?
The ISIN recorded for Compass Therapeutics, Inc. is US20454B1044.
Does aibio.space cover Compass Therapeutics?
aibio.space lists Compass Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Compass Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Compass Therapeutics profitable?
Compass Therapeutics, Inc. reported a net loss of $66.5 million for the fiscal year ended Dec 31, 2025, and used $49.1 million of cash in operations, per its annual report to the SEC.
How much does Compass Therapeutics spend on research and development?
$56.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Compass Therapeutics have?
$179.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Compass Therapeutics (CMPX) stock news?
Our latest story on Compass Therapeutics, dated Aug 12, 2025: "Compass Therapeutics prices $119,999,329 stock and warrant offering at $3.00". Compass is selling 33,290,000 shares and pre-funded warrants for 6,710,000 shares. Proceeds before expenses are $112,800,000. Source.
How long will Compass Therapeutics's cash last?
From our story of Aug 12, 2025: The company estimates that this cash, together with the offering proceeds, will be sufficient to fund its operating expenses into 2028, and it adds that its assumptions may prove wrong and that it could use its capital sooner than it expects. Source.
Investor discussion: Compass Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Compass Therapeutics, Inc.
- CIK
- 1738021
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- CMPX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Phone
- 617-500-8099
- Shares outstanding
- 180,087,915 as of 2026-07-28 (10-Q filed 2026-08-06)
- Former names
- Olivia Ventures, Inc.
Recent filings
Listing details
- Company
- Compass Therapeutics, Inc.
- Ticker
- CMPX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US20454B1044
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction